Skip to main content

Sienna Biopharmaceuticals® to Present at Dermatology Summit and J.P. Morgan Healthcare Conference

January 2, 2019 at 4:30 PM EST

WESTLAKE VILLAGE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna®, is scheduled to present at the 6th Annual Dermatology Summit, Sunday, Jan. 6, 2019, 3:20 p.m. PST, in San Francisco. Dr. Beddingfield is also scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference, Wednesday, Jan. 9, 2019, 11 a.m. PST, in San Francisco.

The presentation at the J.P. Morgan conference will be webcast live and can be accessed through the Investor Relations section of the Company’s website at An archived version of the webcast will be available approximately two hours following the live presentation for 90 days.

About Sienna Biopharmaceuticals

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The Company’s objective is to develop a unique, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.

For more information, visit the Company’s website at


Sean Andrews

Caroline Van Hove

Sienna Logo wR.jpg

Source: Sienna Biopharmaceuticals, Inc.